Literature DB >> 25155359

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.

David E Piccioni1, Albert Lai1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25155359      PMCID: PMC4165427          DOI: 10.1093/neuonc/nou214

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  3 in total

1.  Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Authors:  Mohamed A Hamza; Jacob J Mandel; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Vinay K Puduvalli; John F DeGroot
Journal:  J Neurooncol       Date:  2014-05-07       Impact factor: 4.130

2.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

3.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

  3 in total
  4 in total

1.  Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.

Authors:  Kathryn M Field; John Simes; Anna K Nowak; Lawrence Cher; Helen Wheeler; Elizabeth J Hovey; Christopher S B Brown; Elizabeth H Barnes; Kate Sawkins; Ann Livingstone; Ron Freilich; Pramit M Phal; Greg Fitt; Mark A Rosenthal
Journal:  Neuro Oncol       Date:  2015-06-30       Impact factor: 12.300

2.  Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma.

Authors:  X J Qiao; B M Ellingson; H J Kim; D J J Wang; N Salamon; M Linetsky; A R Sepahdari; B Jiang; J J Tian; S R Esswein; T F Cloughesy; A Lai; L Nghiemphu; W B Pope
Journal:  AJNR Am J Neuroradiol       Date:  2014-12-26       Impact factor: 3.825

Review 3.  Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.

Authors:  Alicia Tosoni; Enrico Franceschi; Rosalba Poggi; Alba A Brandes
Journal:  Curr Treat Options Oncol       Date:  2016-09

Review 4.  Bevacizumab for glioblastoma.

Authors:  Yoshitaka Narita
Journal:  Ther Clin Risk Manag       Date:  2015-12-01       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.